Advanced search
Publication Cover
Therapeutic Delivery Volume 3, 2012 - Issue 9
Submit an article Journal homepage
3,498
Views
0
CrossRef citations to date
0
Altmetric
Review

Functional RNA Delivery Targeted to Dendritic Cells By Synthetic Nanoparticles

Kenneth C McCulloughb Institute of Virology & ImmunoprophylaxisCH-3147Mittelhä[email protected]
,
Isabelle Bassia Institute of Virology & ImmunoprophylaxisCH-3147MittelhäusernSwitzerland
,
Thomas Démoulinsa Institute of Virology & ImmunoprophylaxisCH-3147MittelhäusernSwitzerland
,
Lisa J Thomann-Harwooda Institute of Virology & ImmunoprophylaxisCH-3147MittelhäusernSwitzerland
&
Nicolas Rugglia Institute of Virology & ImmunoprophylaxisCH-3147MittelhäusernSwitzerland
Pages 1077-1099 | Published online: 29 Aug 2012

References

  • McCullough KC , SummerfieldA. Targeting the porcine immune system – particulate vaccines in the 21st century. Dev. Comp. Immunol.33, 394–409 (2009).
  • Thery C , AmigorenaS. The cell biology of antigen presentation in dendritic cells. Curr. Opin. Immunol.13, 45–51 (2001).
  • Randolph GJ , JacubzickC, QuC. Antigen presentation by monocytes and monocyte-derived cells. Curr. Opin. Immunol.20, 52–60 (2008).
  • Jensen PE . Recent advances in antigen processing and presentation. Nat. Immunol.8, 1041–1048 (2007).
  • Rocha N , NeefjesJ. MHC class II molecules on the move for successful antigen presentation. EMBO J.27, 1–5 (2008).
  • Vyas JM , Van der Veen AG, Ploegh HL. The known unknowns of antigen processing and presentation. Nat. Rev. Immunol.8, 607–618 (2008).
  • Collnot E -M, Ali H, Lehr C-M. Nano- and microparticulate drug carriers for targeting of the inflamed intestinal mucosa. J. Control. Release161, 235–246 (2012).
  • Danhier F , AnsorenaE, SilvaJM, CocoR, Le Breton A, Preat V. PLGA-based nanoparticles: an overview of biomedical applications. J. Control. Release161, 505–522 (2012).
  • Hamdy S , HaddadiA, HungRW, LavasanifarA. Targeting dendritic cells with nano-particulate PLGA cancer vaccine formulations. Adv. Drug. Del. Rev.63, 943–955 (2011).
  • Klippstein R , PozoD. Nanotechnology-based manipulation of dendritic cells for enhanced immunotherapy strategies. Nanomedicine6, 523–529 (2010).
  • Pulendran B , AhmedR. Translating innate immunity into immunological memory: implications for vaccine development. Cell124, 849–863 (2006).
  • Shortman K , LahoudMH, CaminschiI. Improving vaccines by targeting antigens to dendritic cells. Exp. Mol. Med.41, 61–66 (2009).
  • Unger WW , van Beelen AJ, Bruijns SC et al. Glycan-modified liposomes boost CD4(+) and CD8(+) T-cell responses by targeting DC-SIGN on dendritic cells. J. Control. Release160, 88–95 (2012).
  • Kumari S , MgS, MayorS. Endocytosis unplugged: multiple ways to enter the cell. Cell Res.20, 256–275 (2010).
  • Sandvig K , PustS, SkotlandT, van Deurs B. Clathrin-independent endocytosis: mechanisms and function. Curr. Opin. Cell Biol.23, 413–420 (2011).
  • Platta HW , StenmarkH. Endocytosis and signaling. Curr. Opin. Cell Biol.23, 393–403 (2011).
  • van Niel G , WubboltsR, StoorvogelW. Endosomal sorting of MHC class II determines antigen presentation by dendritic cells. Curr. Opin. Cell Biol.20, 437–444 (2008).
  • Norbury CC , SigalLJ. Cross priming or direct priming: is that really the question? Curr. Opin. Immunol.15, 82–88 (2003).
  • Kurts C , RobinsonBW, KnollePA. Cross-priming in health and disease. Nat. Rev. Immunol.10, 403–414 (2010).
  • Heath W , BelzG, BehrensGMNet al. Cross-presentation, dendritic cell subsets, and the generation of immunity to cellular antigens. Immunol. Rev. 199, 9–26 (2004).
  • Monu N , TrombettaES. Cross-talk between the endocytic pathway and the endoplasmic reticulum in cross-presentationby MHC class I molecules. Curr. Opin. Immunol.19, 66–72 (2007).
  • Burgdorf S , KurtsC. Endocytosis mechanisms and the cell biology of antigen. Curr. Opin. Immunol.20, 89–95 (2008).
  • Bevan MJ . Cross-priming. Nat. Immunol.7, 363–365 (2006).
  • Blankenstein T , SchulerT. Cross-priming versus cross-tolerance: are two signals enough? Trends Immunol.23, 171–173 (2002).
  • Melief CJ . Mini-review: regulation of cytotoxic T-lymphocyte responses by dendritic cells: peaceful coexistence of cross-priming and direct priming? Eur. J. Immunol.33, 2645–2654 (2003).
  • den Haan JM , BevanMJ. Constitutive versus activation-dependent cross-presentation of immune complexes by CD8(+) and CD8(-) dendritic cells in vivo. J. Exp. Med.196, 817–827 (2002).
  • Moser M . Dendritic cells in immunity and tolerance-do they display opposite functions? Immunity.19, 5–8 (2003).
  • Lutz MB , KurtsC. Induction of peripheral CD4+ T-cell tolerance and CD8+ T-cell cross-tolerance by dendritic cells. Eur. J. Immunol.39, 2325–2330 (2009).
  • Allam JP , BieberT, NovakN. Dendritic cells as potential targets for mucosal immunotherapy. Curr. Opin. Allergy Clin. Immunol.9, 554–557 (2009).
  • Rescigno M . Dendritic cells in oral tolerance in the gut. Cell. Microbiol.13, 1312–1318 (2011).
  • Rescigno M , Di Sabatino A. Dendritic cells in intestinal homeostasis and disease. J. Clin. Invest.119, 2441–2450 (2009).
  • Rescigno M , LopatinU, ChieppaM. Interactions among dendritic cells, macrophages, and epithelial cells in the gut: implications for immune tolerance. Curr. Opin. Immunol.20, 669–675 (2008).
  • Rescigno M , MatteoliG. Lamina propria dendritic cells: for whom the bell TOLLs? Eur. J. Immunol.38, 1483–1486 (2008).
  • Sabatte J , MagginiJ, NahmodKet al. Interplay of pathogens, cytokines and other stress signals in the regulation of dendritic cell function. Cytokine Growth Factor Rev. 18, 5–17 (2007).
  • Chung Y , ChangJH, KweonMN, RennertPD, KangCY. CD8α-11b+ dendritic cells but not CD8α+ dendritic cells mediate cross-tolerance toward intestinal antigens. Blood106, 201–206 (2005).
  • Amigorena S , SavinaA. Intracellular mechanisms of antigen cross presentation in dendritic cells. Curr. Opin. Immunol.22, 109–117 (2010).
  • Belizaire R , UnanueER. Targeting proteins to distinct subcellular compartments reveals unique requirements for MHC class I and II presentation. Proc. Natl Acad. Sci. USA106, 17463–17468 (2009).
  • Markov OO , MironovaNL, MaslovMAet al. Novel cationic liposomes provide highly efficient delivery of DNA and RNA into dendritic cell progenitors and their immature offsets. J. Control. Release 160, 200–210 (2012).
  • Jilek S , MerkleHP, WalterE. DNA-loaded biodegradable microparticles as vaccine delivery systems and their interaction with dendritic cells. Adv. Drug Deliv. Rev.57, 377–390 (2005).
  • Ji W , PanusD, PalumboRN, TangR, WangC. Poly(2-aminoethyl methacrylate) with well-defined chain length for DNA vaccine delivery to dendritic cells. Biomacromolecules12, 4373–4385 (2011).
  • Sun X , ChenS, HanJ, ZhangZ. Mannosylated biodegradable polyethyleneimine for targeted DNA delivery to dendritic cells. Int. J. Nanomed.7, 2929–2942 (2012).
  • Melhem NM , GleasonSM, LiuXD, Barratt-BoyesSM. High-level antigen expression and sustained antigen presentation in dendritic cells nucleofected with wild-type viral mRNA but not DNA. Clin. Vaccine Immunol.15, 1337–1344 (2008).
  • Wykes M , PomboA, JenkinsC, MacPhersonGG. Dendritic cells interact directly with naive B-lymphocytes to transfer antigen and initiate class switching in a primary T-dependent response. J. Immunol.161, 1313–1319 (1998).
  • Le Roux D , Le Bon A, Dumas A et al. Antigen stored in dendritic cells after macropinocytosis is released unprocessed from late endosomes to target B cells. Blood119, 95–105 (2011).
  • Katas H , AlparHO. Development and characterisation of chitosan nanoparticles for siRNA delivery. J. Control. Release115, 216–225 (2006).
  • Gao W , XiaoZ, Radovic-MorenoA, ShiJ, LangerR, FarokzadOC. Progress in siRNA delivery using multifunctional nanoparticles. Methods Mol. Biol.629, 53–67 (2010).
  • Tezuka H , OhtekiT. Regulation of intestinal homeostasis by dendritic cells. Immunol. Rev.234, 247–258 (2010).
  • Nestle FO , Di Meglio P, Qin J-Z, Nickoloff BJ. Skin immune sentinels in health and disease. Nat. Rev. Immunol.9, 679–691 (2009).
  • Romani N , ClausenBE, StoitznerP. Langerhans cells and more: langerin-expressing dendritic cell subsets in the skin. Immunol. Rev.234, 120–141 (2010).
  • Kaplan DH . In vivo function of Langerhans cells and dermal dendritic cells. Trends Immunol.31, 446–451 (2010).
  • Watts C , WestMA, ZaruR. TLR signalling regulated antigen presentation in dendritic cells. Curr. Opin. Immunol.22, 124–130 (2010).
  • Dam TK , BrewerCF. Lectins as pattern recognition molecules: the effects of epitope density in innate immunity. Glycobiology20, 270–279 (2009).
  • Combadiere B , LiardC. Transcutaneous and intradermal vaccination. Hum. Vaccines7, 811–827 (2011).
  • Ueno H , KlechevskyE, SchmittNet al. Targeting human dendritic cell subsets for improved vaccines. Semin. Immunol. 23, 21–27 (2011).
  • Caminschi I , ShortmanK. Boosting antibody responses by targeting antigens to dendritic cells. Trends Immunol.33, 71–77 (2011).
  • Romani N , ThurnherM, IdoyagaJ, SteinmanRM, FlacherV. targeting of antigens to skin dendritic cells: possibilities to enhance vaccine efficacy. Immunol. Cell Biol.88, 424–430 (2010).
  • Stoitzner P , GreenLK, JungJYet al. Tumor immunotherapy by epicutaneous immunization requires Langerhans cells. J. Immunol. 180, 1991–1998 (2008).
  • Garcia-Gaumont C , SeksekO, GrzybowskaJ, BorowskiE, BolardJ. delivery systems for antisense oligonucleotides. Pharmacol. Ther.87, 255–277 (2000).
  • Mahato RI , TakakuraY, HashidaM. Development of targeted delivery systems for nucleic acid drugs. J. Drug Target.4, 337–357 (1996).
  • Henriksen-Lacey M , KorsholmKS, AndersenP, PerrieY, ChristensenD. Liposomal vaccine delivery systems. Exp. Opin. Drug Del.8, 505–519 (2011).
  • Wasungu L , HoekstraD. Cationic lipids, lipoplexes and intracellular delivery of genes. J. Control. Release116, 255–264 (2006).
  • Landesman-Milo D , PeerD. Altering the immune response with lipid-based nanoparticles. J. Control. Release161, 600–608 (2012).
  • Li W , SzokaFC. Lipid-based nanoparticles for nucleic acid delivery. Pharm. Res.24, 438–449 (2007).
  • Slütter B , BalSM, DingZ, JiskootW, BouwstraJA. Adjuvant effect of cationic liposomes and CpG depends on administration route. J. Control. Release154, 123–130 (2011).
  • Hassane FS , SalehAF, AbesR, GaitMJ, LebleuB. Cell penetrating peptides: overview and applications to the delivery of oligonucleotides. Cell. Mol. Life Sci.67, 715–726 (2010).
  • Vazquez-Calvo A , Saiz J-C, McCullough KC, Sobrino F, Martin-Acebes MA. Acid-dependent viral entry. Virus Res.167(2), 125–137 (2012).
  • Mueller J , KretzschmarI, VolkmerR, BoisguerinP. Comparison of cellular uptake using 22 CPPs in 4 different cell lines. Bioconjug. Chem.19, 2363–2374 (2008).
  • Lundin P , JohanssonH, GuterstamPet al. Distinct uptake routes of cell-penetratng peptide conjugates. Bioconjug. Chem. 19, 2535–2542 (2008).
  • Zaro JL , Shen W-C. Quantitative comparison of membrane transduction and endocytosis of oligopeptides. Biochem. Biophys. Res. Commun.307, 241–247 (2003).
  • Tünnemann G , MartinRM, HauptS, PatschC, EdenhoferF, CardosoC. Cargo-dependent mode of uptake and bioavailability of TAT-containing proteins and peptides in living cells. FASEB J.20, 1775–1784 (2006).
  • Summerton JE . A novel reagent for safe, effective delivery of substances into cells. Ann. NY Acad. Sci.1058, 62–75 (2005).
  • Boudier A , Aubert-PlouësselA, GérardinCet al. Tripartite siRNA micelles as controlled delivery systems for primary dendritic cells. Drug Dev. Ind. Pharm. 35, 950–958 (2009).
  • Diaz-Moscoso A , VercauterenD, RejmanJet al. Insights in cellular uptake mechanisms of pDNA-polycationic amphiphilic cyclodextrin nanoparticles (CDplexes). J. Control. Release 143, 318–325 (2010).
  • Dierendonck M , De Koker S, Vervaet C, Remon JP, De Geest BG. Interaction between polymeric multilayer capsules and immune cells. J. Control. Release161, 592–599 (2012).
  • Hu Y , LitwinT, NagarajaARet al. Cytosolic delivery of membrane-impermeable molecules in dendritic cells using pH-responsive core-shell nanoparticles. Nano Lett. 7, 3056–3064 (2007).
  • Hu Y , LuJJ, AtukoralePUet al. Cytosolic delivery mediated via electrostatic surface binding of protein, virus or siRNA cargoes to pH-responsive core-shell gel. Biomacromolecules 10, 756–765 (2009).
  • Howard KA . Delivery of RNA interference therapeutics using polycation-based nanoparticles. Adv. Drug. Del. Rev.61, 710–720 (2009).
  • Laga R , CarlisleR, TangneyM, UlbrichK, SeymourLW. Polymer coatings for delivery of nucleic acid therapeutics. J. Control. Rel.161, 537–553 (2012).
  • Sharma R , GhasparianA, RobinsonJA, McCulloughKC. Synthetic virus-like particles target dendritic cell lipid rafts for rapid endocytosis primarily but not exclusively by macropinocytosis. PLoS ONEe43248 (2012).
  • Midoux P , PichonC, Yaouanc J-J, Jaffrès P-A. Chemical vectors for gene delivery: a current review on polymers, peptides and lipids containing histidine or imidazole as nucleic acids carriers. Br. J. Pharmacol.157, 166–178 (2009).
  • Varkouhi AK , ScholteM, StormG, HaismaHJ. Endosomal escape pathways for delivery of biologicals. J. Control. Release151, 220–228 (2011).
  • Gonzalez-Rodriguez ML , RabascoAM. Charged liposomes as carriers to enhance the permeation through the skin. Exp. Opin. Drug Del.8, 857–871 (2011).
  • Jiang H -L, Kim TH, Kim Y-K, Park I-Y, Cho M-H, Cho CS. Efficient gene delivery using chitosan–polyethylenimine hybrid systems. Biomed. Mater.3(2), 025013 (2008).
  • Won Y -W, Lim KS, Kim Y-H. Intracellular organelle-targeted non-viral gene delivery systems. J. Control. Release152, 99–109 (2011).
  • Nakase I , KobayashiS, FutakiS. Endosome-disruptive peptides for improving cytosolic delivery of bioactive macromolecules. Biopolym. Peptide Sci.94, 763–770 (2010).
  • Hafez IM , MaurerN, CullisPR. On the mechanism whereby cationic lipids promote intracellular delivery of polynucleic acids. Gene Ther.8, 1188–1196 (2001).
  • Tavernier G , AndriesO, DemeesterJ, SandersNN, De Smedt SC, Rejman J. mRNA as gene therapeutic: how to control protein expression. J. Control. Release150, 238–247 (2011).
  • Ceppi M , RuggliN, TacheV, GerberH, McCulloughKC, SummerfieldA. Double-stranded secondary structures on mRNA induce type 1 interferon (IFN a/b) production and maturation of mRNA-transfected monocyte-derived dendritic cells. J. Gene Med.7, 452–465 (2005).
  • Liu MA . Gene-based vaccines: recent developments. Curr. Opin. Mol. Therapy12, 86–93 (2010).
  • Dow SW . Liposome-nucleic acid immunotherapeutics. Exp. Opin. Drug Del.5, 11–24 (2008).
  • Basha G , NovobrantsevaTI, RosinNet al. Influence of cationic lipid composition on gene silencing properties of lipid nanoparticle formulations of siRNA in antigen-presenting cells. Am. Soc. Gene Cell Ther. 19, 2186–2200 (2011).
  • Tesz GJ , AouadiM, ProtMet al. Glucan particles for selective delivery of siRNA to phagocytic cells in mice. Biochem. J. 436, 351–362 (2011).
  • Subramanya S , Kim S-S, Abraham S et al. Targeted delivery of small interfering RNA to human dendritic cells to suppress Dengue Virus infection and associated proinflammatory cytokine production. J. Virol.84, 2490–2501 (2010).
  • Akita H , KogureK, MoriguchiRet al. nanoparticles for ex vivo siRNA delivery to dendritic cells for cancer vaccines: programmed endosomal escape and dissociation. J. Control. Release 143, 311–317 (2010).
  • Kong Y , RuanL, MaL, CuiY, WangJM, LeY. RNA interference as a novel and powerful tool in immunopharmacological research. Int. Immunopharm.7, 417–426 (2007).
  • Davidson BL , McCrayPB. Current prospects for RNA interference-based therapies. Nat. Rev. Gen.12, 329–340 (2011).
  • Akinc A , ZumbuehlA, GoldbergMet al. A combinatorial library of lipid-like materials for delivery of RNAi therapeutics. Nat. Biotechnol. 26, 561–569 (2008).
  • Howard KA , RahbekUL, LiuXet al. RNA interference in vitro and in vivo using a Chitosan siRNA nanoparticle system. Mol. Ther. 14, 476–484 (2006).
  • Rahbek UL , HowardKA, OupickyDet al. Intracellular siRNA and precursor miRNA trafficking using bioresponsive copolypeptides. J. Gene Med. 10, 81–93 (2008).
  • Boudier A , Aubert-PlouësselA, MebarekNet al. Development of tripartite polyion micelles for efficient peptide delivery into dendritic cells without altering their plasticity. J. Control. Release 154, 156–163 (2011).
  • Mockey M , BourseauE, ChandrashekharVet al. mRNA-based cancer vaccine: prevention of B16 melanoma progression and metastasis by systemic injection of MART 1 mRNA histidylated lipopolyplexes. Cancer Gene Ther. 14, 802–814 (2007).
  • Kim H -K, Wei H, Kulkarni A, Pogranichniy RN, Thompson DH. Effective targeted gene delivery to dendritic cells via synergetic interaction of mannosylated lipid with DOPE and BCAT. Biomacromolecules13, 636–644 (2012).
  • Perche F , BenvegnuT, BerchelMet al. Enhancement of dendritic cells transfection in vivo and of vaccintion against B16F10 melanoma with mannosylated histidylated lipopolyplexes loaded with tumor antigen messenger RNA. Nanomedicine 7, 445–453 (2011).
  • Su X , FrickeJ, KavanaghDG, IrvineDJ. In vitro and in vivo mRNA delivery using lipid-enveloped pH-responsive polymer nanoparticles. Mol. Pharm.8, 774–787 (2011).
  • Debus H , BaumhofP, ProbstJ, KisselT. delivery of messenger RNA using poly(ethylene imine)–poly(ethylene glycol)–copolymer blends for polyplex formation: biophysical characterization and in vitro transfection properties. J. Control. Release148, 334–343 (2010).
  • Rejman J , TavernierG, BavarsadN, DemeesterJ, De Smedt SC. mRNA transfection of cervical carcinoma and mesenchymal stem cells mediated by cationic carriers. J. Control. Release147, 385–391 (2010).
  • Khromykh AA . Replicon-based vectors of positive strand RNA viruses. Curr. Opin. Mol. Therapy.2, 555–569 (2000).
  • Mandl CW . Flavivirus immunization with capsid-deletion mutants: basics, benefits, and barriers. Viral Immunol.17, 461–472 (2004).
  • Rayner JO , DrygaSA, KamrudKI. Alphavirus vectors and vaccination. Rev. Med. Virol.12, 279–296 (2002).
  • Atkins GJ , FleetonMN, SheahanBJ. Therapeutic and prophylactic applications of alphavirus vectors. Exp. Rev. Mol. Med.10, e33 (2008).
  • Racanelli V , BehrensSE, AlibertiJ, RehermannB. Dendritic cells transfected with cytopathic self-replicating RNA induce crosspriming of CD8+ T cells and antiviral immunity. Immunity20, 47–58 (2004).
  • Frey CF , BauhoferO, RuggliN, SummerfieldA, HofmannMA, TratschinJD. Classical swine fever virus replicon particles lacking the Erns gene: a potential marker vaccine for intradermal application. Vet. Res.37, 655–670 (2006).
  • Suter R , SummerfieldA, Thomann-HarwoodLJ, McCulloughKC, TratschinJD, RuggliN. Immunogenic and replicative properties of classical swine fever virus replicon particles modified to induce IFN-alpha/beta and carry foreign genes. Vaccine29, 1491–1503 (2011).
  • Suzuki R , WinkelmannER, MasonPW. Construction and characterization of a single-cycle chimeric flavivirus vaccine candidate that protects mice against lethal challenge with dengue virus type 2. J. Virol.83, 1870–1880 (2009).
  • Kucharzik T , LugeringN, RautenbergKet al. Role of M cells in intestinal barrier function. Ann. NY Acad. Sci. 915, 171–183 (2000).
  • Kyd JM , CrippsAW. Functional differences between M cells and enterocytes in sampling luminal antigens. Vaccine26, 6221–6224 (2008).
  • Martin-Latil S , GnadigNF, MalletAet al. Transcytosis of HTLV-1 across a tight human epithelial barrier and infection of sub-epithelial dendritic cells. Blood 120(3), 572–580 (2012).
  • Chieppa M , RescignoM, HuangAY, GermainRN. Dynamic imaging of dendritic cell extension into the small bowel lumen in response to epithelial cell TLR engagement. J. Exp. Med.203, 2841–2852 (2006).
  • Lelouard H , FalletM, de Bovis B, Meresse S, Gorvel JP. Peyer‘s patch dendritic cells sample antigens by extending dendrites through M cell-specific transcellular pores. Gastroenterology142, 592–601 e593 (2012).
  • Rescigno M , UrbanoM, ValzasinaBet al. Dendritic cells express tight junction proteins and penetrate gut epithelial monolayers to sample bacteria. Nat. Immunol. 2, 361–367 (2001).
  • Vallon-Eberhard A , LandsmanL, YogevN, VerrierB, JungS. Transepithelial pathogen uptake into the small intestinal lamina propria. J. Immunol.176, 2465–2469 (2006).
  • Soloff AC , Barratt-BoyesSM. Enemy at the gates: dendritic cells and immunity to mucosal pathogens. Cell Res.20, 872–885 (2010).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.